Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic so...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamata, Kazuhiro, Jindai, Kazuaki, Ichihara, Nao, Saito, Hiroki, Kato, Hideaki, Kunishima, Hiroyuki, Shintani, Ayumi, Nishida, Osamu, Fujitani, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046264/
https://www.ncbi.nlm.nih.gov/pubmed/33853684
http://dx.doi.org/10.1186/s40560-021-00547-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046264/
https://www.ncbi.nlm.nih.gov/pubmed/33853684
http://dx.doi.org/10.1186/s40560-021-00547-7

Ejemplares similares